Clinical Trial Detail

NCT ID NCT03130764
Title Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Adrian Sacher
Indications

lung non-small cell carcinoma

Therapies

Durvalumab + Tremelimumab

Age Groups: senior adult

Additional content available in CKB BOOST